OBJECTIVES: Numerous inflammatory diseases display elevated interleukin (IL)-8, and most are associated with a reactive stroma. IL-8 expression is also elevated in benign prostatic hyperplasia (BPH), yet little is known about reactive stroma in BPH. Whether a reactive stroma response exists in BPH, whether this correlates with elevated IL-8, and whether IL-8 can induce a reactive stroma phenotype have not been determined. This study was designed to specifically address these issues. METHODS: Normal prostate transition zone tissue and BPH specimens, as identified by the Baylor College of Medicine pathology department, were examined by quantitative immunohistochemistry to correlate IL-8, smooth muscle alpha-actin, vimentin, calponin, and tenascin-C. In addition, human prostate stromal cell cultures were used to evaluate the effect of IL-8 on the expression of reactive stroma biomarkers. RESULTS: BPH nodules exhibited elevated epithelial IL-8 immunoreactivity, and this correlated with elevated smooth muscle alpha-actin, reduced calponin, and altered deposition of tenascin-C, relative to the normal prostate transition zone tissue (P <0.05). Multiple vimentin-positive prostate stromal fibroblast cultures were induced by IL-8 to also co-express smooth muscle alpha-actin and tenascin-C, typical of a reactive stroma myofibroblast phenotype. CONCLUSIONS: These data show that BPH reactive stroma is fundamentally different from normal prostate fibromuscular stroma and is typified by the emergence of a reactive stroma myofibroblast phenotype. This reactive stroma pattern correlated spatially with IL-8 elevation in adjacent epithelium. Additionally, IL-8 induced expression of myofibroblast markers in human prostate fibroblasts in vitro. These results suggest that IL-8 acts as a regulator of BPH reactive stroma and is therefore a potential therapeutic target.
OBJECTIVES: Numerous inflammatory diseases display elevated interleukin (IL)-8, and most are associated with a reactive stroma. IL-8 expression is also elevated in benign prostatic hyperplasia (BPH), yet little is known about reactive stroma in BPH. Whether a reactive stroma response exists in BPH, whether this correlates with elevated IL-8, and whether IL-8 can induce a reactive stroma phenotype have not been determined. This study was designed to specifically address these issues. METHODS: Normal prostate transition zone tissue and BPH specimens, as identified by the Baylor College of Medicine pathology department, were examined by quantitative immunohistochemistry to correlate IL-8, smooth muscle alpha-actin, vimentin, calponin, and tenascin-C. In addition, human prostate stromal cell cultures were used to evaluate the effect of IL-8 on the expression of reactive stroma biomarkers. RESULTS: BPH nodules exhibited elevated epithelial IL-8 immunoreactivity, and this correlated with elevated smooth muscle alpha-actin, reduced calponin, and altered deposition of tenascin-C, relative to the normal prostate transition zone tissue (P <0.05). Multiple vimentin-positive prostate stromal fibroblast cultures were induced by IL-8 to also co-express smooth muscle alpha-actin and tenascin-C, typical of a reactive stroma myofibroblast phenotype. CONCLUSIONS: These data show that BPH reactive stroma is fundamentally different from normal prostate fibromuscular stroma and is typified by the emergence of a reactive stroma myofibroblast phenotype. This reactive stroma pattern correlated spatially with IL-8 elevation in adjacent epithelium. Additionally, IL-8 induced expression of myofibroblast markers in human prostate fibroblasts in vitro. These results suggest that IL-8 acts as a regulator of BPH reactive stroma and is therefore a potential therapeutic target.
Authors: Jennifer A Tuxhorn; Gustavo E Ayala; Megan J Smith; Vincent C Smith; Truong D Dang; David R Rowley Journal: Clin Cancer Res Date: 2002-09 Impact factor: 12.531
Authors: Georg E Steiner; Ursula Stix; Alessandra Handisurya; Martin Willheim; Andrea Haitel; Franz Reithmayr; Doris Paikl; Rupert C Ecker; Kristian Hrachowitz; Gero Kramer; Chung Lee; Michael Marberger Journal: Lab Invest Date: 2003-08 Impact factor: 5.662
Authors: Michael J Gerdes; Melinda Larsen; Truong D Dang; Steven J Ressler; Jennifer A Tuxhorn; David R Rowley Journal: Prostate Date: 2004-02-15 Impact factor: 4.104
Authors: Gustavo Ayala; Jennifer A Tuxhorn; Thomas M Wheeler; Anna Frolov; Peter T Scardino; Makoto Ohori; Marcus Wheeler; Jeffrey Spitler; David R Rowley Journal: Clin Cancer Res Date: 2003-10-15 Impact factor: 12.531
Authors: Emily M Chandler; Bo Ri Seo; Joseph P Califano; Roberto C Andresen Eguiluz; Jason S Lee; Christine J Yoon; David T Tims; James X Wang; Le Cheng; Sunish Mohanan; Mark R Buckley; Itai Cohen; Alexander Yu Nikitin; Rebecca M Williams; Delphine Gourdon; Cynthia A Reinhart-King; Claudia Fischbach Journal: Proc Natl Acad Sci U S A Date: 2012-06-04 Impact factor: 11.205
Authors: A Roosen; C Gratzke; A Herrlemann; G Magistro; F Strittmatter; P Weinhold; S Tritschler; C G Stief Journal: Urologe A Date: 2013-02 Impact factor: 0.639
Authors: Mehrnaz Gharaee-Kermani; Jose A Rodriguez-Nieves; Rohit Mehra; Chad A Vezina; Aruna V Sarma; Jill A Macoska Journal: Prostate Date: 2013-03-26 Impact factor: 4.104